SOUTH SAN FRANCISCO, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the ThinkEquity Partners’ G5: The Growth Conference on Monday, September 17, 2007 at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time) at the St. Regis Hotel in San Francisco, California.
To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section (“Investors/Media” tab) and click on the “Events & Webcasts” link provided on the sidebar menu on the page.
About Monogram Biosciences, Inc.
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company’s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company’s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com .
Contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624-4576 Tel: 415 677-2700 amerriweather@monogrambio.comjeremiah.hall@fkhealth.com
Monogram Biosciences, Inc.
CONTACT: Alfred G. Merriweather, Chief Financial Officer of MonogramBiosciences, Inc., +1-650-624-4576, amerriweather@monogrambio.com; orJeremiah Hall of Feinstein Kean Healthcare, +1-415-677-2700,jeremiah.hall@fkhealth.com
Web site: http://www.monogrambio.com/
